NICE sorts out antidiabetics in draft guideline
This article was originally published in Scrip
Executive Summary
A clinical guideline for treating type 2 diabetes in the national health service in England and Wales is being updated to include newer agents for blood glucose control. The National Institute for health and Clinical Excellence(NICE) has published a draft of the guideline for consultation, in which it considers the best use of depeptidyl peptidase-4 inhibitors, thiazolidinediones, the glucagon-like peptide-1 mimetic exenatide (Lilly's Byetta) and long-acting insulin analogues.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.
Need a specific report? 1000+ reports available
Buy Reports